Correlation Between Surrozen and Oncternal Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Surrozen and Oncternal Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Surrozen and Oncternal Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Surrozen and Oncternal Therapeutics, you can compare the effects of market volatilities on Surrozen and Oncternal Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Surrozen with a short position of Oncternal Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Surrozen and Oncternal Therapeutics.

Diversification Opportunities for Surrozen and Oncternal Therapeutics

-0.42
  Correlation Coefficient

Very good diversification

The 3 months correlation between Surrozen and Oncternal is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Surrozen and Oncternal Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncternal Therapeutics and Surrozen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Surrozen are associated (or correlated) with Oncternal Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncternal Therapeutics has no effect on the direction of Surrozen i.e., Surrozen and Oncternal Therapeutics go up and down completely randomly.

Pair Corralation between Surrozen and Oncternal Therapeutics

Given the investment horizon of 90 days Surrozen is expected to generate 0.65 times more return on investment than Oncternal Therapeutics. However, Surrozen is 1.53 times less risky than Oncternal Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Oncternal Therapeutics is currently generating about -0.11 per unit of risk. If you would invest  869.00  in Surrozen on September 16, 2024 and sell it today you would earn a total of  116.00  from holding Surrozen or generate 13.35% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy87.69%
ValuesDaily Returns

Surrozen  vs.  Oncternal Therapeutics

 Performance 
       Timeline  
Surrozen 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Surrozen are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Surrozen displayed solid returns over the last few months and may actually be approaching a breakup point.
Oncternal Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncternal Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Surrozen and Oncternal Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Surrozen and Oncternal Therapeutics

The main advantage of trading using opposite Surrozen and Oncternal Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Surrozen position performs unexpectedly, Oncternal Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncternal Therapeutics will offset losses from the drop in Oncternal Therapeutics' long position.
The idea behind Surrozen and Oncternal Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets